High dose rate interstitial brachytherapy in patients with cancers of the head and neck

L. Yu, B. Vikram, M. Chadha, A. Alfieri, S. Mishra

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

We present our preliminary experience with fractionated high dose rate interstitial brachytherapy (HDR-IBT) in the treatment of head and neck cancers, with or without external beam irradiation, limiting the overall duration of HDR-IBT to one week or less and the maximum number of fractions to ten, delivered twice each day. We treated 12 patients with previously untreated cancers (group 1) to a total median dose of 69.5 Gy by the combination of external beam irradiation (median dose, 50.4 Gy) plus fractionated HDR-IBT (median dose, 16 Gy in six fractions). Fifteen patients with cancer that had recurred after external irradiation, surgery, or both (group 2) were treated by fractionated HDR-IBT (median dose, 28 Gy in seven fractions); seven of them also received additional external irradiation to a median dose of 40 Gy. In group 1, grade 3 or 4 morbidity occurred in none of 12 patients, while in group 2, it occurred in four (26%) of 15 patients. All complications in group 2 were seen in patients who received HDR-IBT to a total dose of 24 Gy or more (4/10 vs 0/5 at lower doses). In groups 1 and 2, the observed survival rate was 45% and 29% at two years, and the local control rate was 79% and 47%, respectively. In general, group 2 patients received lower total doses (but a greater proportion by HDR-IBT) and experienced more local failures and complications, particularly when receiving HDR-IBT doses of 24 Gy or more. In the dose range less than 24 Gy and with a fraction size of 2 to 4 Gy, HDR-IBT was shown to be safe. Our patient population was too heterogeneous to draw meaningful conclusions regarding tumor control.

Original languageEnglish (US)
Pages (from-to)1-6
Number of pages6
JournalEndocurietherapy/Hyperthermia Oncology
Volume12
Issue number1
StatePublished - 1996

Fingerprint

Brachytherapy
Head and Neck Neoplasms
Neoplasms
Survival Rate
Morbidity
Population

Keywords

  • Brachytherapy
  • Head and Neck Cancer
  • High Dose Rate

ASJC Scopus subject areas

  • Cancer Research
  • Radiology Nuclear Medicine and imaging

Cite this

High dose rate interstitial brachytherapy in patients with cancers of the head and neck. / Yu, L.; Vikram, B.; Chadha, M.; Alfieri, A.; Mishra, S.

In: Endocurietherapy/Hyperthermia Oncology, Vol. 12, No. 1, 1996, p. 1-6.

Research output: Contribution to journalArticle

Yu, L, Vikram, B, Chadha, M, Alfieri, A & Mishra, S 1996, 'High dose rate interstitial brachytherapy in patients with cancers of the head and neck', Endocurietherapy/Hyperthermia Oncology, vol. 12, no. 1, pp. 1-6.
Yu, L. ; Vikram, B. ; Chadha, M. ; Alfieri, A. ; Mishra, S. / High dose rate interstitial brachytherapy in patients with cancers of the head and neck. In: Endocurietherapy/Hyperthermia Oncology. 1996 ; Vol. 12, No. 1. pp. 1-6.
@article{63de4d6676c5496cb8b306be61818b12,
title = "High dose rate interstitial brachytherapy in patients with cancers of the head and neck",
abstract = "We present our preliminary experience with fractionated high dose rate interstitial brachytherapy (HDR-IBT) in the treatment of head and neck cancers, with or without external beam irradiation, limiting the overall duration of HDR-IBT to one week or less and the maximum number of fractions to ten, delivered twice each day. We treated 12 patients with previously untreated cancers (group 1) to a total median dose of 69.5 Gy by the combination of external beam irradiation (median dose, 50.4 Gy) plus fractionated HDR-IBT (median dose, 16 Gy in six fractions). Fifteen patients with cancer that had recurred after external irradiation, surgery, or both (group 2) were treated by fractionated HDR-IBT (median dose, 28 Gy in seven fractions); seven of them also received additional external irradiation to a median dose of 40 Gy. In group 1, grade 3 or 4 morbidity occurred in none of 12 patients, while in group 2, it occurred in four (26{\%}) of 15 patients. All complications in group 2 were seen in patients who received HDR-IBT to a total dose of 24 Gy or more (4/10 vs 0/5 at lower doses). In groups 1 and 2, the observed survival rate was 45{\%} and 29{\%} at two years, and the local control rate was 79{\%} and 47{\%}, respectively. In general, group 2 patients received lower total doses (but a greater proportion by HDR-IBT) and experienced more local failures and complications, particularly when receiving HDR-IBT doses of 24 Gy or more. In the dose range less than 24 Gy and with a fraction size of 2 to 4 Gy, HDR-IBT was shown to be safe. Our patient population was too heterogeneous to draw meaningful conclusions regarding tumor control.",
keywords = "Brachytherapy, Head and Neck Cancer, High Dose Rate",
author = "L. Yu and B. Vikram and M. Chadha and A. Alfieri and S. Mishra",
year = "1996",
language = "English (US)",
volume = "12",
pages = "1--6",
journal = "Endocurietherapy/Hyperthermia Oncology",
issn = "8756-1689",
publisher = "Endocurietherapy Research Foundation",
number = "1",

}

TY - JOUR

T1 - High dose rate interstitial brachytherapy in patients with cancers of the head and neck

AU - Yu, L.

AU - Vikram, B.

AU - Chadha, M.

AU - Alfieri, A.

AU - Mishra, S.

PY - 1996

Y1 - 1996

N2 - We present our preliminary experience with fractionated high dose rate interstitial brachytherapy (HDR-IBT) in the treatment of head and neck cancers, with or without external beam irradiation, limiting the overall duration of HDR-IBT to one week or less and the maximum number of fractions to ten, delivered twice each day. We treated 12 patients with previously untreated cancers (group 1) to a total median dose of 69.5 Gy by the combination of external beam irradiation (median dose, 50.4 Gy) plus fractionated HDR-IBT (median dose, 16 Gy in six fractions). Fifteen patients with cancer that had recurred after external irradiation, surgery, or both (group 2) were treated by fractionated HDR-IBT (median dose, 28 Gy in seven fractions); seven of them also received additional external irradiation to a median dose of 40 Gy. In group 1, grade 3 or 4 morbidity occurred in none of 12 patients, while in group 2, it occurred in four (26%) of 15 patients. All complications in group 2 were seen in patients who received HDR-IBT to a total dose of 24 Gy or more (4/10 vs 0/5 at lower doses). In groups 1 and 2, the observed survival rate was 45% and 29% at two years, and the local control rate was 79% and 47%, respectively. In general, group 2 patients received lower total doses (but a greater proportion by HDR-IBT) and experienced more local failures and complications, particularly when receiving HDR-IBT doses of 24 Gy or more. In the dose range less than 24 Gy and with a fraction size of 2 to 4 Gy, HDR-IBT was shown to be safe. Our patient population was too heterogeneous to draw meaningful conclusions regarding tumor control.

AB - We present our preliminary experience with fractionated high dose rate interstitial brachytherapy (HDR-IBT) in the treatment of head and neck cancers, with or without external beam irradiation, limiting the overall duration of HDR-IBT to one week or less and the maximum number of fractions to ten, delivered twice each day. We treated 12 patients with previously untreated cancers (group 1) to a total median dose of 69.5 Gy by the combination of external beam irradiation (median dose, 50.4 Gy) plus fractionated HDR-IBT (median dose, 16 Gy in six fractions). Fifteen patients with cancer that had recurred after external irradiation, surgery, or both (group 2) were treated by fractionated HDR-IBT (median dose, 28 Gy in seven fractions); seven of them also received additional external irradiation to a median dose of 40 Gy. In group 1, grade 3 or 4 morbidity occurred in none of 12 patients, while in group 2, it occurred in four (26%) of 15 patients. All complications in group 2 were seen in patients who received HDR-IBT to a total dose of 24 Gy or more (4/10 vs 0/5 at lower doses). In groups 1 and 2, the observed survival rate was 45% and 29% at two years, and the local control rate was 79% and 47%, respectively. In general, group 2 patients received lower total doses (but a greater proportion by HDR-IBT) and experienced more local failures and complications, particularly when receiving HDR-IBT doses of 24 Gy or more. In the dose range less than 24 Gy and with a fraction size of 2 to 4 Gy, HDR-IBT was shown to be safe. Our patient population was too heterogeneous to draw meaningful conclusions regarding tumor control.

KW - Brachytherapy

KW - Head and Neck Cancer

KW - High Dose Rate

UR - http://www.scopus.com/inward/record.url?scp=0030031257&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030031257&partnerID=8YFLogxK

M3 - Article

VL - 12

SP - 1

EP - 6

JO - Endocurietherapy/Hyperthermia Oncology

JF - Endocurietherapy/Hyperthermia Oncology

SN - 8756-1689

IS - 1

ER -